Supplementary tables

Table 1

Overview of visits and samples for each visit in the donor group.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|   | **1.1**  | **1.2**  | **2.1**  | **2.2**  | **2.3**  | **2.4**  | **2.5**  | **2.6**  | **2.7**  | **2.8**  | **2.9**  | **2.10**  | **3**  |
| **Study day**  | **-40 til 0**  | **0**  | **1-31**  | **2-32**  | **3-33**  | **4-34**  | **5-35**  | **6-36**  | **7-37**  | **8-38**  | **9-39**  | **10-40**  | **28 -35 days after V2.10**  |
| **Visit type**  | **Screening**  | **Screening**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Donation**  | **Followup**  |
| **Informed consent**  | **X**  |   |   |   |   |   |   |   |   |   |   |   |   |
| **Eligibility for study**  | **X**  |   |   |   |   |   |   |   |   |   |   |   |   |
| **Review of medical history**  | **X**  |   |   |   |   |   |   |   |   |   |   |   |   |
| **Current medicine**  | **X**  |   |   |   |   |   |   |   |   |   |   |   |   |
| **Review of the questionnaire sent out**  |   | **X**  |   |   |   |   |   |   |   |   |   |   |   |
| **Submission of calendar**  |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |
| **Demographic**  |   | **X**  |   |   |   |   |   |   |   |   |   |   |   |
| **Objective examination incl. vital values**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Gynecological examination incl. ultrasound scan**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Bloodsamples\***  |   | **X**  |   |   |   |   |   |   |   |   |   |   |   |
| **HIV 1/2**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Hepatitis A, B, C**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **CMV**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Treponema Palladum**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Urine**  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Pregnantcy test**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Urine analysis - culture**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Vaginale swabs**  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Chlamydia trachomatis**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Nesseria gonorrhoeae**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Trichomonas vaginalis**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Mycoplasma genitalium**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Gr. A,B,C,G** **Streptococci**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Fungi**  |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
|            Herpes Simplex (1+2)   |   | **X**  |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Human papilloma virus#**  | **X**  |   |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Mikrobiome analysis**  | **X**  |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |   |
| **CVS for analysis**  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Bacterial count**  |   |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |   |
| **Seamen check**  |   |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |   |
| **pH**  |   |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |   |
| **CVS for VMT**  |   |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |   |
| **Research Biobank**  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Blod**  |   |   |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Urine**  |   |   |   |   |   |   |   |   |   |   |   |   | **X**  |
| **CVS**  |   |   |   |   |   |   |   |   |   |   |   |   | **X**  |
| **Vaginal swab** **Rectal swab** **Microbiome**  |   **X**  |   |   |   |   |   |   |   |   |   |   |   | **X** **X**  |
| **Behavioral recommendations**  |   | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  | **X**  |   |

Table 2

Overview of visits and samples for each visit in the recipients group for RCT study, flowcytometry and antiseptic pretreatment.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cycle day**  |   |   | **1**  | **10**  | **17**  | **1**  | **10**  | **17**  | **1**  | **10**  | **17**  | **1**  | **10**  | **1**  | **10**  | **10**  | **24**  |
| **Visit**  | **1.1**  | **1.2**  |   | **2**  | **3**  |   | **4**  | **5**  |   | **6**  | **7**  |   | **8**  |   | **9**  | **10**  | **11**  |
| **Study day**  | **-28**  | **-14**  |   | **0**  | **7**  |   | **28**  | **35**  |   | **56**  | **63**  |   | **84**  |   | **168**  | **1 cykle after  V9**  | **14 days after V10**  |
| **Buffer in visits days**  | **±14**  | **±13**  |   |   | **±2**  |   | **±2**  | **±2**  |   | **±4**  | **±4**  |   | **±6**  |   | **±12**  | **±2**  | **±2**  |
| **Type of visit**  | **Screening 1**  | **Screening 2**  | **Before BL**  | **Baseline**  | **Intervention**  | **After 1. VMT\*\***  | **Intervention**  | **Intervention**  | **After VMT with Engraftment\*\***  | **Intervention**  | **Follow-up**  | **After VMT with Engraftment\*\***  | **Follow-up**  | **Menstrual blood collection follow -up**  | **Follow-up**  | **Intervention**  | **Followup**  |
| **Informed concent**  | X  |    |   |    |    |   |    |    |   |    |    |   |    |   |    | X  |   |
| **Eligibility for study**  | X  |   |   |   |   |   |   |   |   |   |   |   |   |   |    |   |   |
| **Review of medical history**  | X  |   |   |   |   |   |   |   |   |   |   |   |   |   |    |   |   |
| **Current medicine**  | X  |   |   |   |   |   |   |   |   |   |   |   |   |   |    |   |   |
| **Review of the questionnaire sent out**  |    | X  |   |   |   |   |   |   |   |   |   |   |   |   |    |   |   |
| **Submission of calendar**  |    | X  |   | X  | X  |   | X  | X  |   | X  | X  |   | X  |   | X  |   |   |
| **Demographics**  |    | X  |   |   |   |   |   |   |   |   |   |   |   |   |    |   |   |
| **Sideeffects**  |    |   |   |   | X  |   | X  | X  |   | X  | X  |   | X  |   | X  |   |   |
| **Objective examination incl. vital values**  |    | X  |   | X  | X  |   | X  | X  |   | X  | X  |   | X  |   |   X  | X  | X  |
| **Gynecological examination incl. ultrasound scan**  |    | X  |   |   | X  |   | (X)  |  X  |   | (X)  |  X  |   | X   |   |  X  |   |   |
| **Randomization** |    |    |   | X  |    |   |    |    |   |    |    |   |    |   |    |   |   |
| **VMT procedure** |   |   |   | **X**  |   |   | **(X)**  |   |   | **(X)**  |   |   |   |   |   | **X**  |   |
| **Bloodsamples\*** |    | X  |   |    |    |   |    |    |   |    |    |   |    |   | X  |   |   |
| **HIV 1/2** |    | X  |   |   |   |   |   |   |   |   |   |   |   |   | X  |   |   |
| **Hepatitis A,B,C** |    | X  |   |   |   |   |   |   |   |   |   |   |   |   | X  |   |   |
| **CMV** |    | X  |   |   |   |   |   |   |   |   |   |   |   |   | X  |   |   |
| **Treponema Palladum** |    | X  |   |    |    |   |    |    |   |    |    |   |    |   | X  |   |   |
| **Immuncells** |   |   | X  |   |   |   |   |   | (X)  |   |   | (X)  |   | X  |   |   |   |
| **Menstrual blood** |   |   | X  |   |   |   |   |   | (X)  |   |   | (X)  |   | X  |   |   |   |
| **Urin** |    |    |   |    |    |   |    |    |   |    |    |   |    |   |    |   |   |
| **Urine analysis - culture** |   | X  |   | X  |   |   |   |   |   |   |   |   |   |   | X  |   | X  |
| **Pregnancy** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Vaginal swabs** |    |    |   |    |    |   |    |    |   |    |    |   |    |   |    |   |   |
| **Chlamydia trachomatis** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Nesseria gonorrhoeae** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Trichomonas vaginalis** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Mycoplasma genitalium** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Gr. A,B,C,G Streptococci** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Herpes Simplex (1+2)** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Fungi** |   | X  |   | X  |   |   | X  |   |   | X  |   |   | X  |   | X  |   | X  |
| **Human papilloma virus#** |   | X  |   |   |   |   |   |   |   |   |   |   |   |   | X  |   | X  |
| **Microbiome analysis** | X  |    |   | X  | X  |   | X  | X  |   | X  | X  |   | X  |   | X  |   | X  |
| **Research Biobank** |   |   |   |   |   |   |   |   |   |   |   |   |   |   |    |   |   |
| **Blood** |   |   |   | X  | X  |   | X  | X  |   | X  | X  |   | X  |   | X  | X  | X  |
| **Urine** |   |   |   | X  | X  |   | X  | X  |   | X  | X  |   | X  |   | X  |   |   |
| **CVS** |   |   |   | X  | X  |   | X  | X  |   | X  | X  |   | X  |   | X  | X  | X  |
| **Vaginal swab****Rectal swab****Microbiome** |            X  |   |   | X X  | X X  |   | X X  | X X   |   | X X   | X X   |   | X X   |   | X X   |   |  X  |
| **Behavioral recommendations**  |   | X  |   | X  | X  |   | X  | X  |   | X  | X   |   |    |   |    | X  |   |

Table 3

Inclusion and exclusion criteria for donor and recipients

|  |  |
| --- | --- |
| Inclusion criteria |  |
| Donors | **Recipients** |
| Age 18-40 y/old | Age 18-40 y/old |
| Healthy and premenopausal | Healthy and premenopausal |
| Regular menstrual cycle and amenorrhea because of hormonal contraception | Regular menstrual cycle and amenorrhea because of hormonal contraception |
| Shotgun sequencing of vaginal swab showing normal, healthy microbiota | Shotgun sequencing of vaginal swab showing vaginal dysbiosis |
| Willing to answer personal questions regarding medical history and sexual health, behavior and history | Willing to answer personal questions regarding medical history and sexual health, behavior and history |
| Willing to follow behavioral restrictions during study participation | Willing to follow behavioral restrictions during study participation |
| Willing to collect cervicovaginal fluid up to 12 times | Willing to receive vaginal microbiota transplantation |
| No vaginal symptoms such as abnormal discharge, odor or itching  |  |
| Exclusion criteria |  |
| Donors | **Recipients** |
| Pregnant or nursing | Pregnant, <8 weeks postpartum, nursing or planning a pregnancy in the next 6 months |
| Postmenopausal defined as >12 months amenorrhea with no known explanation | Postmenopausal defined as >12 months amenorrhea with no known explanation |
| IUD removal, cervical cryotherapy or laser treatment <3 months prior to study enrollment | IUD removal, cervical cryotherapy or laser treatment <3 months prior to study enrollment |
| Any condition requiring antibiotic treatment during study participation | Any condition requiring antibiotic treatment during study participation |
| Use of long-term hormonal treatments <3 months prior to study enrollment | Use of long-term hormonal treatments <3 months prior to study enrollment |
| Any condition, medical or psychiatric, assessed by the physician will make it unlikely for the participant to be able to follow the protocol | Any condition, medical or psychiatric, assessed by the physician will make it unlikely for the participant to be able to follow the protocol |
| Unsatisfying screening assessed by the examining physician | Unsatisfying screening assessed by the examining physician |
| Participation in other clinical trials <30 days prior to study enrollment | Participation in other clinical trials <30 days prior to study enrollment |
| Any history with BV, VD, treponema pallidum, M. genitalium, HPV including condylomas and CIN, herpes simplex 1+2, infections related to the pelvis, recurring UTI | Known infection with HIV, AIDS or other immune disease |
| N. gonorrhea or C. trachomatis <1 year prior to study participation |  |
| Positive HPV-test |  |
| Risk behavior assessed by the examining physician, including, use of medicine, travel and sexual behavior |  |
| Donors screened with positive CMV-IgG can be paired with CMV-IgG positive recipients |  |
| Hysterectomized |  |

Table 4

Overview of adverse events in relation to VMT material and total registration of AE’s in VMT and placebo group.



